ACR PI-RADs guidelines suggest anti-spasmodic agents may be beneficial for some patients during multi-parametric prostate MRI (mpMRI). Recent evidence suggests that the anti-spasmodic scopolamine butylbromide improves image quality on mpMRI. However, no studies have evaluated intramuscular (IM) injected glucagon. This retrospective IRB approved single-center study performed data-mining of 2595 mpMRI radiology reports (693 with glucagon) and subjective image quality assessment of 63 mpMRI exams (32 with glucagon). No significant benefit of IM glucagon for prostate evaluation was found on mpMRI. Our findings suggest that the risks associated with IM glucagon (medication side effects, patient discomfort, cost) may outweigh any benefits.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords